PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/11, C07K 14/65, A61K 48/00

A2

(11) International Publication Number: WO 99/18195

(43) International Publication Date: 15 April 1999 (15.04.99)

(21) International Application Number: PCT/IL98/00486

(22) International Filing Date: 4 October 1998 (04.10.98)

(30) Priority Data:
08/943,608 3 October 1997 (03.10.97) US

(71) Applicant *(for all designated States except US)*: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, 91042 Jerusalem (IL).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HOCHBERG, Abraham [IL/IL]; Bait Ha'arava Street 40, 93389 Jerusalem (IL). AYESH, Suhail [-/IL]; Shech Khalil Street 18, Wadi El-Gour, Jerusalem (IL).

(74) Agent: REINHOLD COHN AND PARTNERS; P.O. Box 4060, 61040 Tel Aviv (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHODS AND COMPOSITIONS FOR INDUCING TUMOR-SPECIFIC CYTOTOXICITY



A schematic presentation of the plasmids containing the different promoters and enhancers.

(57) Abstract

The invention relates to the specific expression of heterologous sequences, particularly genes encoding cytotoxic products, in tumor cells under the control of regulatory transcriptional sequences. Particularly preferred promoters inlcude H19 regulatory sequences, the IGF-1 promoter and the IGF-2 P3 and P4 promoters. The invention provides expression constructs and methods of administering such expression constructs. The compositions and methods of the invention are useful in the treatment of cancer.